WuXi Biologics (HK:2269), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), said on Friday that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.

This marks the sixth consecutive year that WuXi Biologics has received this honour.

According to WuXi Biologics, this recognition highlights the company's commitment to advancing sustainability throughout its global business operations and value chain, and demonstrates the success of its long-term sustainability strategy and its vision as a Green CRDMO leader.

In July 2025, WuXi Biologics was also placed in Sustainalytics' highest ESG rating tier of negligible risk, achieving a top 1% global ranking score.